

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Genesense Technologies Inc.	07/10/2007

RECEIVING PARTY DATA

Name:	Lorus Therapeutics Inc.
Street Address:	2 Meridian Road
City:	Toronto
State/Country:	CANADA
Postal Code:	M9W 4Z7

PROPERTY NUMBERS Total: 9

Property Type	Number
Patent Number:	6121000
Patent Number:	5998383
Patent Number:	7223849
Patent Number:	6593305
Patent Number:	6472376
Patent Number:	6610539
Patent Number:	7087580
Patent Number:	6566514
Patent Number:	6417169

CORRESPONDENCE DATA

Fax Number: (613)563-7671

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: (613) 567-0762

Email: rgenest@mbm.com

Correspondent Name: MBM & Co.

Address Line 1: 270 Albert Street

PATENT

500313270

REEL: 019541 FRAME: 0983

OP \$360.00 6121000

Address Line 2:	Suite 1400
Address Line 4:	Ottawa, CANADA K1P 5G8

ATTORNEY DOCKET NUMBER:	335-181PAT
-------------------------	------------

NAME OF SUBMITTER:	Rosemary Genest
--------------------	-----------------

Total Attachments: 7
source=Assignment from Genesense to Lorus#page1.tif
source=Assignment from Genesense to Lorus#page2.tif
source=Assignment from Genesense to Lorus#page3.tif
source=Assignment from Genesense to Lorus#page4.tif
source=Assignment from Genesense to Lorus#page5.tif
source=Assignment from Genesense to Lorus#page6.tif
source=Assignment from Genesense to Lorus#page7.tif

CANADA

)

Province of Ontario

)

)

On this 10TH day of July, 2007, before me, Vanessa Grant, a Notary Public in and for the Province of Ontario, personally appeared **Aiping Young**, personally known to me or proven on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her capacity, and that by her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.



A NOTARY PUBLIC IN AND FOR THE
PROVINCE OF ONTARIO

ASSIGNMENT OF INVENTION


In consideration of One (\$1.00) Dollar and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we, **GENESENSE TECHNOLOGIES INC.** (hereinafter "the Assignor"), do hereby sell, assign and transfer to **LORUS THERAPEUTICS INC.** (hereinafter "the Assignee"), all our right, title and interest throughout the world in and to (1) the inventions relating to and described and/or claimed in the patent applications and patents listed in Schedule A; (2) all improvements, including but not limited to modifications, additions, substitutions, derivatives, and deletions to said invention(s); (3) the patent applications and patents listed in Schedule A and national phase applications thereof; (4) all other applications for Letters Patent in any country throughout the world for said invention(s) and improvements, including but not limited to all divisional, continuation, continuation-in-part, renewal, reissue, and substitute applications; (5) any Letters Patent which may issue from any of said applications as exemplified in (3) and (4) above in any country throughout the world; (6) all Convention or Treaty rights derived from any of said applications, including without limitation, all rights of priority throughout the world in and to said applications; and (7) the full and complete right to file applications for Letters Patent in the name of the Assignee, or in our name at the Assignee's election, on said invention(s) and improvements in all countries throughout the world.

For said consideration, the Assignor agrees, upon the request and at the expense of the Assignee, its successors and assigns, to execute any and all divisional, continuation, continuation-in-part, reissue and substitute applications for said invention(s) and improvements, and acknowledge and agree that all rights therein shall vest in the Assignee, its successors and assigns, whereby said Letters Patent will be held and enjoyed by said Assignee, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment had not been made. In addition, the Assignor will, at the request of the Assignee, execute any and all documents required by the Assignee to fully and properly vest the aforementioned rights in the Assignee.

The undersigned hereby grants to the firm of **MBM & CO.** whose full post office address is P.O. Box 809, Station B, Ottawa, Ontario, Canada, K1P 5P9, the power to insert on this assignment any further information and/or correct any clerical error in the information pertaining to the referenced applications and patents, which may be necessary or desirable in order to comply with the patent legislation for recordation of this document.

FOR THE ASSIGNOR:

SIGNED at Toronto, Ontario, Canada, this 10TH day of JULY, 2007.


Signature: 

Name: AIPING YOUNG

Title: PRESIDENT & CEO
GENESENSE TECHNOLOGIES INC.

2 Meridian Road, Toronto, Ontario M9W 4Z7, Canada


I was personally present and did see AIPING YOUNG duly sign and execute the above assignment.


(Signature of witness)

VANESSA GRANT
(Name of witness)

FOR THE ASSIGNEE:

SIGNED at Toronto, Ontario, Canada, this 10TH day of JULY, 2007.


Signature: 

Name: AIPING YOUNG

Title: PRESIDENT & CEO
LORUS THERAPEUTICS INC.

2 Meridian Road, Toronto, Ontario M9W 4Z7, Canada

I was personally present and did see AIPING YOUNG duly sign and execute the above assignment.


(Signature of witness)

VANESSA GRANT
(Name of witness)

Schedule A**ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS OF
RIBONUCLEOTIDE REDUCTASE
(GTI-2501)**

Country	Filed	Serial #	Patent #
AUSTRALIA	2/9/2000	25292/00	780455
CANADA	2/9/2000	2,366,487	
EUROPE (Germany, Spain, France, Italy, Great Britain)	2/9/2000	903456.2	1153128
ISRAEL	2/9/2000	144727	
JAPAN	2/9/2000	2000-598631	
MEXICO	2/9/2000	2001/008137	
NEW ZEALAND	2/9/2000	514090	514090
UNITED STATES	2/11/1999	09/249,730	6,121,000
ARGENTINA	2/11/2000	P000100613	

**ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCTASE R1 AND
USES THEREOF IN THE TREATMENT OF CANCER
(GTI-2501 in combination with chemotherapy)**

Country	Filed	Serial #
CANADA	5/21/2004	2,526,393
EUROPE	5/21/2004	04734192.0
UNITED STATES	5/21/2004	10/557,853

**ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST RIBONUCLEOTIDE REDUCTASE
(GTI-2040)**

Country	Filed	Serial #	Patent #
UNITED STATES	8/1/1997	08/904,901	5,998,383

**ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS
OF RIBONUCLEOTIDE REDUCTASE**
(GTI-2040)

Country	Filed	Serial #	Patent #
AUSTRALIA	8/1/1997	36175/97	738592
CANADA	8/1/1997	2,262,776	2,262,776
CHINA	8/1/1997	97198163.9	97198163.9
EUROPE (Germany, Spain, France, Italy, Great Britain)	8/1/1997	97932690.7	917569
ISRAEL	8/1/1997	128124	
JAPAN	8/1/1997	10-507410	
NEW ZEALAND	8/1/1997	333802	333802
SINGAPORE	8/1/1997	9900413-7	61306
UNITED STATES	5/29/2003	10/447,136	

**ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCTASE R1 AND
USES THEREOF IN THE TREATMENT OF CANCER**
(GTI-2040 in combination with chemotherapy)

Country	Filed	Serial #
AUSTRALIA	2/10/2004	2004209579
CANADA	2/10/2004	2,535,650
EUROPE	2/10/2004	4709557.5
JAPAN	2/10/2004	2006-501413
UNITED STATES	2/10/2004	10/545,152

**ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCTASE R2
AND USES THEREOF IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCER**
(GTI-2040 in combination with cytokines)

Country	Filed	Serial #
AUSTRALIA	1/12/2005	2005203822
CANADA	1/12/2005	2,553,211
EUROPE	1/12/2005	5706393.5
JAPAN	1/12/2005	2006-548057
UNITED STATES	1/12/2005	10/585,772

OLIGONUCLEOTIDES FROM THE UNTRANSLATED REGIONS OF RIBONUCLEOTIDE REDUCTASE AND THEIR USE TO MODULATE CELL GROWTH

(U-sense)

Country	Filed	Serial #	Patent #
CANADA	6/30/1997	2,259,123	2,259,123

INHIBITING NEOPLASTIC CELLS UTILIZING THE RIBONUCLEOTIDE REDUCTASE UTR

(U-sense)

Country	Filed	Serial #
UNITED STATES	5/10/2002	09/214,386
UNITED STATES	8/8/2005	11/198,351

ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS OF RIBONUCLEOTIDE REDUCTASE

(R1 antisense excluding GTI-2501)

Country	Filed	Serial #	Patent #
UNITED STATES	2/11/1999	09/249,247	6,593,305

SUPPRESSION OF MALIGNANCY UTILIZING RIBONUCLEOTIDE REDUCTASE R1

(R1 Gene Therapy)

Country	Filed	Serial #	Patent #
AUSTRALIA	3/18/1998	64922/98	742176
CANADA	3/18/1998	2,301,874	
EUROPE (Germany, Spain, France, Italy, Great Britain)	3/18/1998	98910553.1	971731
HONG KONG	3/18/1998	104079.6	1024640
JAPAN	3/18/1998	10-539987	
SINGAPORE	3/18/1998	9904590-8	68137
UNITED STATES	3/18/1998	09/155,246	6,472,376
UNITED STATES	8/20/2002	10/223,655	

ANTISENSE OLIGONUCLEOTIDE SEQUENCES AS INHIBITORS OF MICROORGANISMS

Country	Filed	Serial #	Patent #
CANADA	7/10/1998	2,294,305	2,294,305
UNITED STATES	7/9/1998	09/112,580	6,610,539

**NEUROPILIN ANTISENSE OLIGONUCLEOTIDE SEQUENCES AND METHODS OF
USING SAME TO MODULATE CELL GROWTH**
(GTI-3611)

Country	Filed	Serial #	Patent #
AUSTRALIA	4/23/1999	34022/99	747639
MEXICO	4/23/1999	10277	
UNITED STATES	3/19/2002	09/296,264	7,087,580

**OLIGONUCLEOTIDE SEQUENCES COMPLEMENTARY TO THIOREDOXIN OR THIOREDOXIN
REDUCTASE GENES AND METHODS OF USING SAME TO MODULATE CELL GROWTH**
(GTI-2601; GTI-3008)

Country	Filed	Serial #	Patent #
AUSTRALIA	1/29/1999	22612/99	760396
CHINA	1/29/1999	99802489.9	
MEXICO	1/29/1999	7455	
UNITED STATES	1/29/1999	09/601,144	6,566,514

**INSULIN-LIKE GROWTH FACTOR II ANTISENSE OLIGONUCLEOTIDE SEQUENCES
AND METHODS OF USING SAME TO MODULATE CELL GROWTH**
(GTI-4006)

Country	Filed	Serial #	Patent #
AUSTRALIA	4/23/1999	34021/99	749802
CANADA	4/23/1999	2,326,825	
MEXICO	4/23/1999	10215	
UNITED STATES	4/22/1999	09/295,593	6,417,169

**SMALL INTERFERING RNA MOLECULES AGAINST RIBONUCLEOTIDE REDUCTASE
AND USES THEREOF**
(siRNA)

Country	Filed	Serial #
CANADA	8/18/2005	2,577,036
EUROPE	8/18/2005	5774823.8
UNITED STATES	8/18/2005	11/573,879

**PREPARATIONS OF ANTISENSE OLIGONUCLEOTIDES AGAINST THIOREDOXIN
AND USES THEREOF**
(GTI-2601/Sumitomo collaboration)

Country	Filed	Serial #
UNITED STATES	4/9/2007	60/910,689